BioCentury | Dec 20, 2004
Company News

DFB management update

...as VP of R&D of its Phyton Biotech Inc. subsidiary, formerly SVP of R&D at Protarga Inc. WIR...
BioCentury | Dec 20, 2004
Company News

Locus management update

...Robert Dickey IV as VP of finance and CFO; formerly president, CEO and CFO of Protarga Inc. WIR...
BioCentury | Nov 15, 2004
Strategy

Melanoma pipeline

...interferon alfa-2b Ph III Schering-Plough, Enzon Taxoprexin Paclitaxel linked to docosahexaenoic acid (DHA) Ph III Protarga...
BioCentury | May 26, 2003
Finance

Ebb & Flow

...13 life science plays, which include proteomics play Epigenomics and U.S.-based cancer and neurology company Protarga...
BioCentury | Oct 7, 2002
Finance

Pummeling the microcaps

...funk, IPO dreams continue to fall by the wayside. Last week's withdrawals include Corcept and Protarga...
...shares at $14-$16 through U.S. Bancorp Piper Jaffray; CIBC World Markets; and Thomas Weisel Partners. Protarga...
...a pharmaceutical agent, to develop therapeutics for cancer, CNS disorders and infectious diseases. Last week, Protarga...
BioCentury | Oct 7, 2002
Clinical News

Taxoprexin DHA-paclitaxel: Phase III pivotal

...infusions of either 900 mg/m2 of Taxoprexin or 1000 mg/m2 of dacarbazine every three weeks. Protarga...
...Phase III trial of Taxoprexin to treat pancreatic cancer, subject to the availability of financing. Protarga Inc....
BioCentury | Oct 4, 2002
Financial News

Two IPOs pulled

...Corcept and Protarga withdrew their IPOs, citing market conditions. Corcept (Menlo Park, Calif.), which is in...
...at $14-$16. Bankers were U.S. Bancorp Piper Jaffray; CIBC World Markets; and Thomas Weisel Partners. Protarga...
BioCentury | Oct 3, 2002
Clinical News

Protarga starting two cancer Phase IIIs

...will compare survival in patients receiving infusions of either Taxoprexin or dacarbazine every three weeks. Protarga...
BioCentury | Aug 5, 2002
Company News

Icos, Protarga deal

...The companies partnered to develop new small molecule anti-cancer drug candidates. Under the deal, Protarga will...
...acid-based targeting technology against ICOS's preclinical library of cell cycle checkpoint and DNA repair antagonists. Protarga...
...drug uptake by cancer cells and to sustain localized therapeutic concentration. Icos Corp. (ICOS),Bothell, Wash. Protarga Inc....
BioCentury | Jul 29, 2002
Company News

Protarga, Icos small molecule cancer deal

...Protarga (King of Prussia, Penn.) and ICOS partnered to develop small molecule cancer compounds. Protarga will...
Items per page:
1 - 10 of 29
BioCentury | Dec 20, 2004
Company News

DFB management update

...as VP of R&D of its Phyton Biotech Inc. subsidiary, formerly SVP of R&D at Protarga Inc. WIR...
BioCentury | Dec 20, 2004
Company News

Locus management update

...Robert Dickey IV as VP of finance and CFO; formerly president, CEO and CFO of Protarga Inc. WIR...
BioCentury | Nov 15, 2004
Strategy

Melanoma pipeline

...interferon alfa-2b Ph III Schering-Plough, Enzon Taxoprexin Paclitaxel linked to docosahexaenoic acid (DHA) Ph III Protarga...
BioCentury | May 26, 2003
Finance

Ebb & Flow

...13 life science plays, which include proteomics play Epigenomics and U.S.-based cancer and neurology company Protarga...
BioCentury | Oct 7, 2002
Finance

Pummeling the microcaps

...funk, IPO dreams continue to fall by the wayside. Last week's withdrawals include Corcept and Protarga...
...shares at $14-$16 through U.S. Bancorp Piper Jaffray; CIBC World Markets; and Thomas Weisel Partners. Protarga...
...a pharmaceutical agent, to develop therapeutics for cancer, CNS disorders and infectious diseases. Last week, Protarga...
BioCentury | Oct 7, 2002
Clinical News

Taxoprexin DHA-paclitaxel: Phase III pivotal

...infusions of either 900 mg/m2 of Taxoprexin or 1000 mg/m2 of dacarbazine every three weeks. Protarga...
...Phase III trial of Taxoprexin to treat pancreatic cancer, subject to the availability of financing. Protarga Inc....
BioCentury | Oct 4, 2002
Financial News

Two IPOs pulled

...Corcept and Protarga withdrew their IPOs, citing market conditions. Corcept (Menlo Park, Calif.), which is in...
...at $14-$16. Bankers were U.S. Bancorp Piper Jaffray; CIBC World Markets; and Thomas Weisel Partners. Protarga...
BioCentury | Oct 3, 2002
Clinical News

Protarga starting two cancer Phase IIIs

...will compare survival in patients receiving infusions of either Taxoprexin or dacarbazine every three weeks. Protarga...
BioCentury | Aug 5, 2002
Company News

Icos, Protarga deal

...The companies partnered to develop new small molecule anti-cancer drug candidates. Under the deal, Protarga will...
...acid-based targeting technology against ICOS's preclinical library of cell cycle checkpoint and DNA repair antagonists. Protarga...
...drug uptake by cancer cells and to sustain localized therapeutic concentration. Icos Corp. (ICOS),Bothell, Wash. Protarga Inc....
BioCentury | Jul 29, 2002
Company News

Protarga, Icos small molecule cancer deal

...Protarga (King of Prussia, Penn.) and ICOS partnered to develop small molecule cancer compounds. Protarga will...
Items per page:
1 - 10 of 29